The Mount Sinai Hospital is renovated to house 190 beds and adds an isolation building, allowing more admissions of contagious cases.

Arpad G. Gerster, MD, an early advocate of aseptic procedure, publishes the first American work on asepsis with photos of The Mount Sinai Hospital.

Arpad G. Gerster, MD, House Surgeon at The Mount Sinai Hospital, publishes the first American work on Listerian surgery, illustrated with photographs taken in the operating rooms at The Mount Sinai Hospital.

George E. Brewer, MD, introduces rubber gloves to The Mount Sinai Hospital and is the first to describe Brewer's kidney, a fulminating infectious process characterized by multiple septic infarcts.

Arpad G. Gerster, MD, House Surgeon at The Mount Sinai Hospital, publishes the first American work on Listerian surgery, illustrated with photographs taken in the operating rooms at The Mount Sinai Hospital.

Arpad G. Gerster, MD, House Surgeon at The Mount Sinai Hospital, publishes the first American work on Listerian surgery, illustrated with photographs taken in the operating rooms at The Mount Sinai Hospital.

Mount Sinai microbiologist, Gregory Shwartzman, MD, wins an American Medical Association gold medal, class I, for his research on creating immunity against bacterial diseases.

Shalom Hirschman, MD, appointed the first Chief of the Infectious Diseases Division in the Department of Medicine.

Mount Sinai Beth Israel doctors encounter AIDS for the first time. The patient is a 33-year-old West German who had lived in Haiti before coming to New York. As a result, Beth Israel physicians are among the first to recognize AIDS as a new entity.

Mount Sinai Beth Israel opens an outpatient clinic for patients with AIDS.

Mount Sinai Beth Israel participates in a national clinical trial of azidothymidine AZT for the treatment of AIDS. Donna Mildvan, MD, Chief of Infectious Diseases, serves as the Principal Investigator for trials offered to people with HIV/AIDS. Beth Israel also establishes an Office of AIDS Coordinator to coordinate activities related to AIDS care.

Mount Sinai Beth Israel is featured in a one-hour Dan Rather program on AIDS on prime-time television.

Mount Sinai Beth Israel participates in a national clinical trial of azidothymidine AZT for the treatment of AIDS. Donna Mildvan, MD, Chief of Infectious Diseases, serves as the Principal Investigator for trials offered to people with HIV/AIDS. Beth Israel also establishes an Office of AIDS Coordinator to coordinate activities related to AIDS care.

Mount Sinai Beth Israel participates in a national clinical trial of azidothymidine AZT for the treatment of AIDS. Donna Mildvan, MD, Chief of Infectious Diseases, serves as the Principal Investigator for trials offered to people with HIV/AIDS. Beth Israel also establishes an Office of AIDS Coordinator to coordinate activities related to AIDS care.

Mount Sinai Beth Israel participates in a national clinical trial of azidothymidine AZT for the treatment of AIDS. Donna Mildvan, MD, Chief of Infectious Diseases, serves as the Principal Investigator for trials offered to people with HIV/AIDS. Beth Israel also establishes an Office of AIDS Coordinator to coordinate activities related to AIDS care.

Mount Sinai Beth Israel participates in a national clinical trial of azidothymidine AZT for the treatment of AIDS. Donna Mildvan, MD, Chief of Infectious Diseases, serves as the Principal Investigator for trials offered to people with HIV/AIDS. Beth Israel also establishes an Office of AIDS Coordinator to coordinate activities related to AIDS care.

The Robert Mapplethorpe Foundation donated $ 1 million to Mount Sinai Beth Israel to create and name an AIDS health-related facility in memory of Robert Mapplethorpe, a renowned photographer.

The Infectious Disease Clinic at The Mount Sinai Hospital is renamed the Jack Martin Fund Clinic in memorial to Jack Martin who died from polio. His family donated funds to Mount Sinai to provide care to persons, particularly women and children with AIDS.

In partnership with Mount Sinai Beth Israel, The Robert Mapplethorpe AIDS Residence opens at 327 East 17th St.

A consortium led by The Mount Sinai Hospital receives a five-year, $6 million grant from NIH to create the Manhattan HIV Brain Bank to research the neurological and neuropsychological manifestations of HIV.

The Robert Mapplethorpe Foundation donated $ 1 million to Mount Sinai Beth Israel to create and name an AIDS health-related facility in memory of Robert Mapplethorpe, a renowned photographer.

The first annual Peter Nicholas Memorial infectious diseases lecture is held in the Department of Medicine.

Mount Sinai Beth Israel treats two patients for bubonic plague, the first case seen in New York for over a century.

The Mount Sinai Hospital receives federal funds to build a bio-containment facility, a level three facility, aiding in the study of infectious agents and the development of new treatment methods.

Icahn Mount Sinai receives a new NIH Center Grant with a total award of more than $20 million over five years for a Center for Investigation of Viral Immunity and Antagonism.

Icahn Mount Sinai receives a grant for $16.8 million from National Institute of Allergy and Infectious Diseases for the Program for Research on Immune Modeling and Experimentation.

The National Institute of Allergy and Infectious Diseases announced that the Icahn School of Medicine at Mount Sinai is a new Center of Excellence for Influenza Research and Surveillance and awards $23 million per year for seven years.

Mount Sinai opens a new facility in Chelsea, taking over an HIV/AIDS care outpatient program formerly run by the St. Vincent’s Catholic Medical Center.

The Mount Sinai Hospital implements a sepsis early-warning and response program on eight floors using the e-medical record system.

The St. Luke’s Roosevelt Hospital Center (now Mount Sinai Morningside) for Comprehensive Care—a pioneer in HIV and AIDS care— formally changes its name to the Spencer Cox Center for Health.

The Division of Infectious Diseases announces the formation of the Institute for Advanced Medicine, a newly integrated organization that will provide comprehensive, state-of-the-art treatment to patients living with HIV/AIDS.

Judith A. Aberg, MD becomes System Chief of Infectious Diseases and establishes the Clinical and Translational Research Center to create clinical trial research units at each of the six locations of the Institute of Advanced Medicine. The NIH-supported Randomized Trial to Prevent Vascular Events in HIV opens, for which Dr. Aberg serves as a national Vice-Chair.

To combat Ebola outbreaks, infectious diseases faculty help create and train staff in the Biocontainment Unit, located in the courtyard on The Mount Sinai Hospital campus.

As part of ongoing efforts to reduce healthcare-associated infections at The Mount Sinai Hospital, bathing inpatients with chlorhexidine gluconate is now the standard of care.

The Arnhold Institute for Global Health at Icahn Mount Sinai teams up with software maker Dimagi and TulaSalud to assess risks for a Zika epidemic in vulnerable parts of Guatemala.

Mount Sinai Health System issues a broadcast email about the Zika virus, which was just declared by World Health Organization to be a public health emergency.

Adolfo Garcia-Sastre, PhD, then the Director of the Global Health and Emerging Pathogens Institute contributes to Janet Tobias’ documentary “Unseen Enemy.”

Mount Sinai becomes Pasteur Institute's first U.S. partner and announces they are forming a joint research unit to study viral pathogens, known as the Artificial Virus Evolution Unit.

The Hepatitis C Clinical and Research Program broadens the scope of services offered and is rebranded as the Respectful and Equitable Access to Comprehensive Healthcare Program.

The Blood and Body Fluid Exposure Program at The Mount Sinai Hospital and Icahn Mount Sinai is transitioned from Infection Prevention to Employee Health Services.

Researchers at Icahn Mount Sinai receive a contract award of up to $132 million from the National Institute of Allergy and Infectious Diseases, as part of a new Collaborative Influenza Vaccine Innovation Centers program to further develop the universal flu vaccine.

Icahn Mount Sinai Professor of Microbiology, Florian Krammer, PhD, receives a Grand Challenge for Universal Influenza Vaccine Development grant.

Infectious Diseases faculty and fellows implement clinical trials for COVID-19 across the Mount Sinai Health System including antivirals, immunomodulatory therapies, and convalescent plasma contributing to the licensing of agents. The COVID Clinical Trials Unit is established and merged with the Clinical and Translational Research Center.

Judith A. Aberg, MD is selected to be a member of the NIH COVID-19 Treatment Guidelines. Gopi Patel, MD, and Judith A. Aberg, MD, spearhead the Mount Sinai Health System COVID-19 Treatment Guidance along with colleagues in pharmacy, pulmonary, critical care, and hospital administration. COVID-19 treatment approval committees are established at each hospital facility.

Icahn Mount Sinai creates a LGBT+ Fellowship in Medicine. The first incumbent is Roy Zucker, MD, from Israel.

Dynavax announces it will work with Icahn Mount Sinai on a universal influenza vaccine and receives funding from the National Institute of Allergy and Infectious Diseases to develop a vaccine and aims to use Dynavax's adjuvant technology to support that process.

Applied UV, Inc. installs first ultraviolet light disinfecting devices at Mt. Sinai Morningside Hospital as part of evaluation study.

Icahn Mount Sinai researchers publish results from an early clinical trial of a novel influenza virus vaccine that induces immune responses to a wide range of virus strains.

A phase 1 anti-coronavirus hyper-immunoglobulin study for inpatient treatment begins at The Mount Sinai Hospital.

Judith A. Aberg, MD, is appointed as Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai.

The National Institute of Allergy and Infectious Diseases awards $10 million in first-year funding to establish a clinical research network of eight institutions called Childhood Asthma in Urban Settings, including Icahn Mount Sinai.

The National Institute of Allergy and Infectious Diseases awards Icahn Mount Sinai a seven-year contract valued at more than $42 million to advance basic research into influenza and COVID-19, and prepare for future pandemics.

Icahn Mount Sinai receives a grant of more than $4 million to evaluate anal cancer screening in high-risk women.

Judith A. Aberg, MD, is featured in the documentary “Pharma Bro” profiling Martin Shkreli. Pharma Bro was nominated for four Leo Awards and won Best Sound in a Feature Length Documentary.

Icahn Mount Sinai announces hiring Beverly Forsyth, MD as the new Director of Education Infection Prevention and Emergency Preparedness.

Icahn Mount Sinai announces the launch of a phase 1 trial of an egg-based NDV-HXP-S COVID-19 vaccine developed in the Department of Microbiology and led by Sean Liu MD, PhD. Mount Sinai announces the formation of CastleVax, Inc. to further develop novel vaccines and therapeutics.

Researchers at Icahn Mount Sinai are awarded an initial $16 million from NIH to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.

Mount Sinai enrolls the first study participant to receive bispecific dual affinity retargeting molecule, MGD020, that binds to HIV-1-envelope, GP41, for recognition and elimination by CD3-expressing T lymphocytes.

Ana Fernandez-Sesma, PhD, is appointed Chair of the Department of Microbiology at Icahn Mount Sinai.

NIH awards Icahn Mount Sinai a five-year, $13 million grant to create vaccines against existing and emerging coronaviruses.

CastleVax receives Project NexGen award valued at up to $338 million from the Biomedical Advanced Research and Development Authority, based on the preliminary findings from the phase 1 NDV-HXP-S clinical trial conducted by Sean Liu MD, PhD.

NIH awards $1.3 million to a project run by Icahn Mount Sinai that involves teens finding and studying pathogens that could cause future outbreaks.

Access to Mount Sinai Health System's infectious disease guidance and antimicrobial prescribing information is made available through a new clinical decision to support the application known as Firstline.